文献速递心力衰竭与心肌病

恩格列净在心力衰竭患者中跨越左室射血分数谱的效应

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究 pooled 分析 EMPEROR-Reduced 和 EMPEROR-Preserved 试验共 9718 例患者,按左室射血分数(LVEF)分组评估恩格列净对心衰结局的影响。结果显示,恩格列净降低心血管死亡或心衰住院风险,主要来自减少心衰住院;在 LVEF <25% 至 <65% 各组中效应相似(HR 0.63–0.73),但 LVEF ≥65% 组效应减弱(HR 1.05,95%CI 0.70–1.58)。

要点

  • 恩格列净在 LVEF <25% 至 <65% 各组均降低心衰住院风险约30%,效应一致。
  • LVEF ≥65% 患者中恩格列净对心衰住院的效应减弱,HR 1.05(95%CI 0.70–1.58)。
  • 性别不影响恩格列净的疗效反应。

核心结论

  • 恩格列净对心衰结局的效应在 LVEF <25% 至 <65% 患者中临床有意义且相似,但在 LVEF ≥65% 患者中减弱。

研究设计与样本

  • 对 EMPEROR-Reduced 和 EMPEROR-Preserved 试验进行的 pooled 分析,共纳入 9718 例患者(恩格列净组 4860 例,安慰剂组 4858 例),按 LVEF 分组:<25%(n=999)、25–34%(n=2230)、35–44%(n=1272)、45–54%(n=2260)、55–64%(n=2092)、≥65%(n=865)。

主要发现

  • 随着 LVEF 从 <25% 增至 ≥65%,心血管死亡和心衰住院风险逐渐下降。
  • 恩格列净降低心血管死亡或心衰住院风险,主要通过减少心衰住院实现。
  • 恩格列净降低心衰住院风险的 HR(95%CI)分别为:LVEF <25%:0.73(0.55–0.96);25–34%:0.63(0.50–0.78);35–44%:0.72(0.52–0.98);45–54%:0.66(0.50–0.86);55–64%:0.70(0.53–0.92);≥65%:1.05(0.70–1.58)。
  • 其他心衰结局及 KCCQ 评估的健康状态呈现相似的反应模式。
  • 性别不影响恩格列净的治疗反应。

临床怎么用

  • 对于 LVEF <65% 的心衰患者,恩格列净可一致地降低心衰住院风险,临床可考虑使用。
  • 对于 LVEF ≥65% 的心衰患者,恩格列净对心衰住院的效应可能减弱,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: No therapy has shown to reduce the risk of hospitalization for heart failure across the entire range of ejection fractions seen in clinical practice. We assessed the influence of ejection fraction on the effect of the sodium-glucose cotransporter 2 inhibitor empagliflozin on heart failure outcomes. METHODS AND RESULTS: A pooled analysis was performed on both the EMPEROR-Reduced and EMPEROR-Preserved trials (9718 patients; 4860 empagliflozin and 4858 placebo), and patients were grouped based on ejection fraction: <25% (n = 999), 25-34% (n = 2230), 35-44% (n = 1272), 45-54% (n = 2260), 55-64% (n = 2092), and ≥65% (n = 865). Outcomes assessed included (i) time to first hospitalization for heart failure or cardiovascular mortality, (ii) time to first heart failure hospitalization, (iii) total (first and recurrent) hospitalizations for heart failure, and (iv) health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The risk of cardiovascular death and hospitalization for heart failure declined progressively as ejection fraction increased from <25% to ≥65%. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization, mainly by reducing heart failure hospitalizations. Empagliflozin reduced the risk of heart failure hospitalization by ≈30% in all ejection fraction subgroups, with an attenuated effect in patients with an ejection fraction ≥65%. Hazard ratios and 95% confidence intervals were: ejection fraction <25%: 0.73 (0.55-0.96); ejection fraction 25-34%: 0.63 (0.50-0.78); ejection fraction 35-44%: 0.72 (0.52-0.98); ejection fraction 45-54%: 0.66 (0.50-0.86); ejection fraction 55-64%: 0.70 (0.53-0.92); and ejection fraction ≥65%: 1.05 (0.70-1.58). Other heart failure outcomes and measures, including KCCQ, showed a similar response pattern. Sex did not influence the responses to empagliflozin. CONCLUSION: The magnitude of the effect of empagliflozin on heart failure outcomes was clinically meaningful and similar in patients with ejection fractions <25% to <65%, but was attenuated in patients with an ejection fraction ≥65%. KEY QUESTION: How does ejection fraction influence the effects of empagliflozin in patients with heart failure and either a reduced or a preserved ejection fraction? KEY FINDING: The magnitude of the effect of empagliflozin on heart failure outcomes and health status was similar in patients with ejection fractions <25% to <65%, but it was attenuated in patients with an ejection fraction ≥65%. TAKE HOME MESSAGE: The consistency of the response in patients with ejection fractions of <25% to <65% distinguishes the effects of empagliflozin from other drugs that have been evaluated across the full spectrum of ejection fractions in patients with heart failure.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Butler, Packer, Filippatos, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022. PMID: 34878502. doi:10.1093/eurheartj/ehab798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。